Education
About Us
Working with TipRanks
Follow Us
Omeros Corporation (GB:0KBU)
:0KBU
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.46Last Year’s EPS
-0.97Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 15, 2025
|% Change Since: -19.87%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a cautious optimism. While there are significant positive developments, particularly with debt restructuring and progress toward narsoplimab approval, the increase in net loss, decline in OMIDRIA sales, and pausing of certain clinical programs present notable challenges.Company Guidance
During the earnings call for Omeros Corporation, the company provided guidance on its financial and strategic positioning for the first quarter of fiscal year 2025. The net loss for the quarter was reported at $33.5 million, or $0.58 per share, compared to a $31.4 million loss, or $0.54 per share, in the previous quarter. As of March 31, 2025, Omeros held $52.5 million in cash and investments. The company announced a debt restructuring agreement, exchanging $71 million in 2026 convertible notes for new 9.5% convertible senior notes due in 2029, and converting $10 million of the 2026 notes into equity. This reduced their total debt by $10 million and lowered near-term repayment obligations from $118 million to $17 million. Omeros highlighted ongoing efforts to secure additional capital to support operations, particularly the anticipated approval and launch of narsoplimab for the treatment of TA-TMA, with a target FDA action date of September 25, 2025. The company is also progressing on its marketing authorization application for narsoplimab with European regulators and continuing its development programs for zaltenibart, a treatment for PNH, and the PDE7 inhibitor program for cocaine use disorder.Debt Restructuring and Financial Flexibility
Omeros announced an exchange agreement reducing their outstanding debt by $10 million and lowering near-term repayment obligations by over $100 million, extending debt maturity to 2029. This improves financial flexibility and strengthens the balance sheet.
Narsoplimab Approval Progress
FDA accepted the resubmitted BLA for narsoplimab for TA-TMA, assigning a target action date of September 25th. Narsoplimab is positioned as the first approved treatment for TA-TMA and represents a nearly $1 billion annual market opportunity.
Strong Market Potential for Zalutenibart
The ongoing clinical trial for zaltenibart in PNH indicates potential for significant market share in a growing PNH treatment market, projected to be over $10 billion by 2032.
OMIDRIA Royalties
OMIDRIA royalties for the first quarter totaled $6.7 million based on net sales of $22.3 million, highlighting ongoing revenue from this product.
GB:0KBU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0KBU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 15, 2025 | $4.03 | $3.42 | -15.16% |
Mar 31, 2025 | $8.33 | $7.97 | -4.26% |
Nov 13, 2024 | $4.31 | $6.03 | +40.03% |
Aug 07, 2024 | $4.41 | $3.79 | -13.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Omeros Corporation (GB:0KBU) report earnings?
Omeros Corporation (GB:0KBU) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Omeros Corporation (GB:0KBU) earnings time?
Omeros Corporation (GB:0KBU) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Omeros Corporation stock?
The P/E ratio of Omeros is N/A.
What is GB:0KBU EPS forecast?
GB:0KBU EPS forecast for the fiscal quarter 2025 (Q2) is -0.46.